{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:55:28Z","timestamp":1781546128706,"version":"3.54.5"},"reference-count":37,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2026,2,20]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>We evaluated the safety, acceptability, and cost-effectiveness of all published studies on fluoroquinolone (FQ)-based TB preventive treatment (TPT) regimens in all settings and populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We searched for studies published between February 2014 and September 2023 using PubMed, Embase, Turning Research Into Practice (TRIP), Global Health Library, and the Cochrane Central Register of Controlled Trials. Meta-analysis was conducted using random effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twenty-two observational and modelling studies evaluating FQ-based TPT were included, assessing outcomes of safety (n = 16), acceptability (n = 9), and cost-effectiveness (n = 2). Only 2% (95% confidence interval [CI]: 0%\u20134%) of children and adolescents and 8% (95% CI: 2%\u201314%) of adults discontinued FQ monotherapy due to drug-related adverse events (AEs). Compared to FQ monotherapy, rates of drug-related AEs of any severity were non-significantly higher with multidrug FQ regimens without pyrazinamide (PZA). Pooled discontinuation rates were 50% (95% CI: 34%\u201367%) among children and 57% (95% CI: 16%\u201398%) among adult contacts treated with PZA-containing FQ-based regimens. Pooled acceptance rates exceeded 80% among all groups. FQ-based TPT was cost-effective to avert TB-related deaths and loss of quality-adjusted life-years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>These results complement the evidence from two recent randomised trials. FQ monotherapy is a safe, acceptable, and cost-effective TPT regimen for contacts exposed to multidrug-resistant or rifampicin-resistant TB disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5588\/ijtldopen.26.0019","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:26:12Z","timestamp":1781544372000},"page":"364-375","source":"Crossref","is-referenced-by-count":0,"title":["Fluoroquinolones for TB preventive treatment of contacts exposed to persons with multidrug-resistant TB: a systematic review and meta-analysis"],"prefix":"10.5588","volume":"3","author":[{"given":"H.","family":"Sidhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kanchar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Schenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2026061510260548000_3.6.364.1","unstructured":"World Health Organization . Global tuberculosis report 2023. Geneva: WHO, 2024."},{"key":"2026061510260548000_3.6.364.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"2026061510260548000_3.6.364.3","unstructured":"World Health Organization . The end TB strategy. Geneva: WHO, 2015."},{"issue":"24","key":"2026061510260548000_3.6.364.4","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","article-title":"Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam The VQUIN MDR Trial","volume":"391","author":"Fox","year":"2024","journal-title":"New Eng J Med"},{"key":"2026061510260548000_3.6.364.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314318"},{"issue":"1","key":"2026061510260548000_3.6.364.6","doi-asserted-by":"crossref","first-page":"EVIDoa2400190","DOI":"10.1056\/EVIDoa2400190","article-title":"A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis","volume":"4","author":"Duong","year":"2025","journal-title":"NEJM Evid"},{"issue":"2","key":"2026061510260548000_3.6.364.7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2026061510260548000_3.6.364.8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmi.2023.09.015","article-title":"Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"30","author":"Zhou","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026061510260548000_3.6.364.9","unstructured":"World Health Organization . Guidelines on the management of latent tuberculosis infection. Geneva: WHO, 2015."},{"key":"2026061510260548000_3.6.364.10","unstructured":"Wells GS , The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute, 2000. https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale."},{"key":"2026061510260548000_3.6.364.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010761"},{"key":"2026061510260548000_3.6.364.12","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000063"},{"key":"2026061510260548000_3.6.364.13","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000260"},{"issue":"3","key":"2026061510260548000_3.6.364.14","doi-asserted-by":"crossref","first-page":"ofad087","DOI":"10.1093\/ofid\/ofad087","article-title":"Tuberculosis diagnosis and preventive monotherapy among children and adolescents exposed to rifampicin-resistant tuberculosis in the household","volume":"10","author":"Apolisi","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026061510260548000_3.6.364.15","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0028"},{"issue":"6","key":"2026061510260548000_3.6.364.16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.pneumo.2015.05.003","article-title":"[Children exposed to multidrug-resistant tuberculosis: how should we manage? Analysis of 46 child contacts and review of the literature]","volume":"71","author":"Catho","year":"2015","journal-title":"Rev Pneumol Clin"},{"issue":"3","key":"2026061510260548000_3.6.364.17","doi-asserted-by":"crossref","first-page":"00149","DOI":"10.1183\/23120541.00149-2021","article-title":"Latent tuberculosis infection among contacts of patients with multidrug-resistant tuberculosis in New South Wales, Australia","volume":"7","author":"Chang","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026061510260548000_3.6.364.18","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0092"},{"issue":"11","key":"2026061510260548000_3.6.364.19","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.5588\/ijtld.13.0872","article-title":"Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation","volume":"18","author":"Garcia-Prats","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026061510260548000_3.6.364.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01865-18"},{"issue":"2","key":"2026061510260548000_3.6.364.21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5588\/ijtld.21.0443","article-title":"Fluoroquinolone preventive therapy for children exposed to MDR-TB","volume":"26","author":"Gureva","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"2026061510260548000_3.6.364.22","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/cid\/ciaa327","article-title":"Risk factors for adverse events in household contacts prescribed preventive treatment for drug-resistant tuberculosis exposure","volume":"72","author":"Malik","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2026061510260548000_3.6.364.23","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1093\/cid\/ciz502","article-title":"Tuberculosis preventive therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen","volume":"70","author":"Malik","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026061510260548000_3.6.364.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70034-9"},{"key":"2026061510260548000_3.6.364.25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit655"},{"key":"2026061510260548000_3.6.364.26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.nmni.2016.03.010","article-title":"Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays","volume":"12","author":"Bedini","year":"2016","journal-title":"New Microbes New Infect"},{"key":"2026061510260548000_3.6.364.27","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.9.701.34065"},{"issue":"2","key":"2026061510260548000_3.6.364.28","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multi-drug-resistant tuberculosis","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ"},{"issue":"3","key":"2026061510260548000_3.6.364.29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3201\/eid2103.141313","article-title":"Moxifloxacin prophylaxis against MDR TB, New York, New York, USA","volume":"21","author":"Trieu","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"2026061510260548000_3.6.364.30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.21.0760","article-title":"Caregiver willingness to give TPT to children living with drug-resistant TB patients","volume":"26","author":"Rouzier","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"2026061510260548000_3.6.364.31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/cid\/ciz254","article-title":"Willingness to take multidrug-resistant tuberculosis (MDR-TB) preventive therapy among adult and adolescent household contacts of MDR-TB index cases: an international multisite cross-sectional study","volume":"70","author":"Suryavanshi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2026061510260548000_3.6.364.32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/INF.0000000000002268","article-title":"Acceptability of a novel levofloxacin dispersible tablet formulation in young children exposed to multidrug-resistant tuberculosis","volume":"38","author":"Purchase","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"2026061510260548000_3.6.364.33","doi-asserted-by":"crossref","first-page":"e0268560","DOI":"10.1371\/journal.pone.0268560","article-title":"Practical and psychosocial challenges faced by caregivers influence the acceptability of multidrug-resistant tuberculosis preventive therapy for young children","volume":"17","author":"Wademan","year":"2022","journal-title":"PLoS One"},{"key":"2026061510260548000_3.6.364.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201501-0069OC"},{"issue":"7","key":"2026061510260548000_3.6.364.35","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1016\/S2214-109X(22)00113-9","article-title":"The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study","volume":"10","author":"Dodd","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026061510260548000_3.6.364.36","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"issue":"31","key":"2026061510260548000_3.6.364.37","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2013United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.26.0019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:26:16Z","timestamp":1781544376000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.26.0019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.5588\/ijtldopen.26.0019"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.26.0019","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}